GLP1R and vitreous hemorrhage: In this study, semaglutide (a long-acting GLP-1R agonist) showed an unexpectedly higher rate of severe DR complications (i.e., vitreous hemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation).71